



September 4, 2012

Astex Pharmaceuticals to Participate on Epigenetics Panel at Rodman & Renshaw Conference

DUBLIN, Calif., Sept. 4, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced that James S.J. Manuso, PhD, chairman and chief executive officer, will participate in a Rodman & Renshaw Global Investment Conference panel discussion titled, "Epigenetics: The Silent Revolution in Oncology Research" on Monday, September 10th at 9:15 a.m. ET in New York.

Key opinion leader Jean-Pierre Issa, MD, director, Fels Institute for Cancer Research and Molecular Biology, Temple University will also be speaking on the panel, amongst others.

About Astex Pharmaceuticals

Astex Pharmaceuticals is dedicated to the discovery and development of novel small molecule therapeutics with a focus on oncology. The Company is developing a proprietary pipeline of novel therapies and is creating de-risked products for partnership with leading pharmaceutical companies. Astex Pharmaceuticals developed Dacogen® (decitabine) for Injection and receives significant royalties on global sales.

For more information about Astex Pharmaceuticals, Inc., please visit <http://www.astx.com>.

The Astex Pharmaceuticals, Inc. logo is available at <http://www.globenewswire.com/newsroom/prs/?pkgid=12273>

CONTACT: Timothy L. Enns

Astex Pharmaceuticals, Inc.

Senior Vice President

Corporate Communications & Marketing

Tel: +1 (925) 560-2810

E-mail: tim.enns@astx.com

Susanna Chau

Astex Pharmaceuticals, Inc.

Manager

Investor Relations

Tel: +1 (925) 560-2845

E-mail: susanna.chau@astx.com

Alan Roemer

The Trout Group

Managing Director

Tel: +1 (646) 378-2945

E-mail: aroemer@troutgroup.com

Kari Watson

MacDougall Biomedical Communications

Senior Vice President

Tel: +1 (781) 235-3060

E-mail: kwatson@macbiocom.com